|
|
References Myasthenia Gravis Video Dr David Hilton-Jones. General/Review Articles. 1. Drachman DB. 1994. Myasthenia gravis. N Engl J Med 330: 1797-1810. 2. Engel AG (Editor). 1999. Myasthenia gravis and myasthenic disorders. Oxford University Press. ISBN 0-19-512970-9 - includes authoritative chapters on MG, LEMS and Congenital Myasthenias. 3. Vincent A, Palace J and Hilton-Jones D. 2001 Myasthenia gravis. Lancet 357: 2122-8. 4. Palace J, Vincent A. and Beeson D. 2001. Myasthenia gravis: diagnostic and management dilemmas. Curr. Opin Neurol. 14: 583-9. 5. Newsom-Davis J. and Beeson D. 2001. Myasthenia gravis and myasthenic syndromes; in Disorders of Voluntary Muscle, eds Karpati G, Hilton-Jones D and Griggs R. pp 650-675. Cambridge University Press. 6. a very useful general website: www.neuro.wustl.edu/neuromuscular/synmg.html Symptoms. 7. Jaretzki A, Barohn RJ et al 2000. Myasthenia gravis: recommendations for clinical research standards. Task Force of Myasthenia Gravis Foundation of America. Ann Thorac Surg. 70:327-34. 8. Wirtz PW, Verschuuren JJ et al. 2002. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiat. 73:766-8. 9. Kaminski HJ, Ruff RL et al. 1990. Why are eye muscles frequently involved in MG? Neurology 40: 1663-1669. 10. Barton JJ and Fouladvand M. 2000. Ocular aspects of MG. Semin Neurol. 20: 7-20. Diagnosis. 11. Vincent A and Newsom-Davis J. 1985. Acetylcholine receptor antibody as a diagnostic test for MG: results in 153 validated and 2967 diagnostic assays. J Neurol Neurosurg Psychiat. 48:1246-52. 12. Engstrom JW 2004. Myasthenia gravis: diagnostic mimics. Semin Neurol. 24:141-7. Treatment. 13. Richman DP and Agius M. 2003. Treatment of autoimmune myasthenia gravis. Neurology 61:1652-61. 14. Newsom-Davis J. 2003. Therapy in MG and Lambert-Eaton myasthenic syndrome. Seminars in Neurology 23: 191-8. 15. Pinching AJ, Peters DK and Newsom-Davis J. 1976. Remission of MG following plasma exchange. Lancet ii. 1373-6. 16. Wiles CM, Webster AD et al. 2002. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry. 72:440-8. 17. Palace J, Newsom-Davis and Lecky B. 1998. A randomized double-blind trial of prednisolone alone or in combination with azathioprine in MG. Neurology 50: 1778-1783. 18. Evoli A, Batocchi A-P, Minisci C, DiSchino C and Tonali P. 2001. Therapeutic options in ocular MG. Neuromuscul Disord. 11:208-16. 19. Jaretzki A, Steinglass KM and Sonett JR. 2004. Thymectomy in the management of MG. Semin Neurol. 24: 49-62. 20. Gronseth GS, Barohn RJ al. 2000. Practice parameter: thymectomy for MG (an evidence-based review) Neurology 55: 7-15. 21. Dillon FX. 2004. Anesthesia issues in the perioperative management of MG. Semin Neurol. 24:83-94. Scientific. 22. Vincent A. 2002. Unravelling the pathogenesis of MG. Nature Revs Immunol. 2:797-804. Typical but 'seronegative' MG - Ie without anti-acetylcholine receptor antibodies. 23. Vincent A, Bowen J, Newsom-Davis J and McConville J. 2003. Seronegative generalised MG: clinical features, antibodies and their targets. Lancet Neurology. 2: 99-106. 24. Hoch W, McConville J, Vincent A et al. 2001. Autoantibodies to the receptor tyrosine kinase MuSK in patients with MG without anti-AChR antibodies. Nature Medicine. 7: 365-8. 25. Evoli A et al 2003.Clinical correlates with anti-MuSK antibodies in generalized seronegative MG. Brain 126:2304-11. 26. Sanders D, Vincent A et al. 2003. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 60:1978-80. 27. Mossman S, Vincent A and Newsom-Davis J. 1986. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet. 1986; i:116-9. Historic. 28. Keynes Sir G, 1983. The history of MG. Medical History. V: 313 - 326. 29. Walker MB. 1934.Treatment of MG with physostigmine. Lancet i:1200. 30. Chang CC and Lee CY. 1963. Isolation of neurotoxins from Bungarus multicinctus, and their modes of neuromuscular blocking action. Arch Int Pharmacodyn Ther. 144. 241-257. 31. Simpson JA 1960. MG; a new hypothesis. Scott Med J. 5: 419- 439. 32. Fambrough DM, Drachman DB and Satyamurti S. 1973. Neuromuscular junction in MG; decreased acetylchloline receptors. Science 182: 293-5. 33. Patrick J and Lindstrom JM. 1973. Autoimmune response to acetylcholine receptor. Science. 180: 871-2. 34. Compston DAS, Vincent A, Newsom-Davis J and Batchelor JR. 1980. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in MG. Brain 103: 579-601. The Lambert-Eaton myasthenic syndrome (LEMS) Video Prof John Newsom-Davis. 41. O'Neill JH, Murray NM, Newsom-Davis J. 1988. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 111 :577-96. 42. Newsom-Davis J and Lang B. 1999. pp 251-297 in Engel AG (Editor). Myasthenia Gravis and myasthenic disorders. Oxford University Press ISBN 0-19-512970-9. 6. a very useful general website: www.neuro.wustl.edu/neuromuscular/synmg.html Symptoms. 8. Wirtz PW, Verschuuren JJ et al. 2002. Difference in distribution of muscle weakness between myasthenia gravis and the LEMS syndrome. J Neurol Neurosurg Psychiat. 73:766-8. Treatment. 14. Newsom-Davis J. 2003. Therapy in MG and LEMS. Seminars in Neurology 23: 191-8. 43. Bain PG, Vincent A, Lang B et al. 1996. Effects of IvIg on muscle weakness and calcium channel antibodies in the LEMS. Neurology 47: 678-683. Diagnosis. 44. Motomura M, Lang B, Newsom-Davis J et al. 1995. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiat. 58:85-7. Aetiology and lung cancer in the LEMS. 45. Roberts A, Perera S, Lang B, Vincent A and Newsom-Davis J. 1985. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 317: 737-9. 46. Maddison P, Newsom-Davis J, Mills KR and Souhami, RL. 1999. Favourable prognosis in the Lambert-Eaton myasthenic syndrome and small cell lung carcinoma. Lancet 353: 117-8. 47. Wirtz PW, Willcox N, Verschuuren JJGM et al. 2004. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol. (in press). 48. Chalk CH, Newsom-Davis J, Spiro SG et al. 1990. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 40:1552-6. 49. Wirtz PW, Verschuuren JJ et al. 2004. Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families. J Neurol. 251:1255-9. Historic LEMS papers. 50. Lambert EH, Eaton LM and Rooke ED. 1956. Defect of neuromuscular conduction associated with malignant neoplasia. Am J Physiol. 187:612-3. 51. Lang B, Newsom-Davis J, Wray D, Vincent A and Murray N. 1981. Autoimmune aetiology for the myasthenic (Eaton-Lambert) syndrome. Lancet ii: 224-6. 3, 4 Diamino-pyridine. 52. To get 3, 4 diamino-pyridine (3,4 DAP), Doctors - and only doctors - can approach the Pharmacy Department, Radcliffe Infirmary, Woodstock Road, Oxford, OX2 6HE, Tel 01865 224783. Congenital myasthenias video Prof John Newsom-Davis. NB none of the Congenital Myasthenias is autoimmune in any way, so immuno-suppressive treatments and thymectomy are completely unsuitable for them. NB watch the highlighted names for new progress in this fast-moving field. 61. Ohno K, Engel AG, Sine S. The spectrum of congenital myasthenia syndromes. Mol Neurobiol 2002. 26:347-367. 62. Engel AG, Ohno K, and Sine SM.1999. Congenital myasthenic syndromes. pp 205-228 in Engel AG (Ed). Myasthenia gravis and myasthenic disorders. Oxford University Press ISBN 0-19-512970-9. 63. Newsom-Davis J and Beeson D. 2001. Myasthenia gravis and myasthenic syndromes; in Disorders of Voluntary Muscle, 7th edition; eds Karpati G, Hilton-Jones D and Griggs R. pp 650-675. Cambridge University Press. 64. Burke G, Cossins J, Maxwell S, Robb S, Nicolle M, Vincent A, Newsom-Davis J, Palace J, Beeson D. 2004. Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromusc Disord. 14:356-64. 65. Palace J, Wiles CM, Newsom-Davis J. 1991. 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia. J Neurol Neurosurg Psychiat. 54:1069-72. 66. Useful websites: On www.genetests.org there is a link via 'gene reviews' to an excellent overview by Lochmuller. There is another at www.neuro.wustl.edu/neuromuscular/synmg.html 67. The Oxford Muscle Centre: Contact for pre-referral forms: Somai.Man@orh.nhs.uk For appointments: claudia.cooper@orh.nhs.uk Tel 01865 224097 Chief Scientist/ address for completed preferral forms: Prof David Beeson, Neuroscience Group, Weatherall Institute for Molecular Medicine, Headington, Oxford, OX3 9DS. |